20191218 Financial calendar 2020 EN
Year: 2019
Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
20191212 PR TG4010_EN_results
Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
20191211 PR preclinical BT001 EN
Transgene Announces Investor Meetings for January 2020
20191209 PR Investors Meeting agenda 2020
Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
https://www.transgene.fr/wp-content/uploads/posters/Poster-actox2019.pdf Clémentine Spring-Giusti et al. American College of Toxicology – 40th Annual Meeting Download the poster here Poster Presentation
Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001
20191114 Résultats T3-2019 EN
Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Poster 0710-AASLD 2019-TG1050-T101_Metaanalyse Fabien Zoulim et al. AASLD 2019 Download the poster here Poster Presentation
Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
Transgene SITC 2019 Poster Jean-Baptiste Marchand et al. SITC 2019 Download the poster here Poster Presentation
Transgene Will Participate in the Jefferies 2019 London Healthcare Conference
20191022 – Transgene PR Jefferies EN
First efficacy results of TG4001+avelumab in HPV16-positive cancers
https://channel.royalcast.com/webcast/transgene/20191003_1/